The Experts below are selected from a list of 21264 Experts worldwide ranked by ideXlab platform

Kanwaljit Chopra - One of the best experts on this subject based on the ideXlab platform.

  • lycopene attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain
    European Journal of Pain, 2008
    Co-Authors: Anurag Kuhad, Sameer Sharma, Kanwaljit Chopra
    Abstract:

    Diabetic neuropathic pain, an important Microvascular Complication of diabetes mellitus is recognized as one of the most difficult types of pain to treat. The development of tolerance, inadequate relief and potential toxicity of classical antinociceptives warrant the investigation of the newer agents to relieve this pain. The aim of the present study was to explore the antinociceptive effect of lycopene and its effect on tumour necrosis factor-alpha (TNF-alpha) and nitric oxide (NO) release in streptozotocin induced diabetic mice. Four weeks after a single intraperitoneal injection of streptozotocin (200 mg/kg), mice were tested in the tail immersion and hot-plate assays. Diabetic mice exhibited significant hyperalgesia alongwith increased plasma glucose and decreased body weights as compared with control mice. Lycopene (1, 2 and 4 mg/kg body weight; per oral) treatment, from the 4th to 8th week after streptozotocin injection, significantly attenuated thermal hyperalgesia and the hot-plate latencies. Lycopene also inhibited the TNF-alpha and NO release in a dose dependent manner. These results indicate an antinociceptive activity of lycopene possibly through its inhibitory action on NO and TNF-alpha release and point towards its potential to attenuate diabetic neuropathic pain.

  • effect of resveratrol a polyphenolic phytoalexin on thermal hyperalgesia in a mouse model of diabetic neuropathic pain
    Fundamental & Clinical Pharmacology, 2007
    Co-Authors: Sameer Sharma, Srinivas K Kulkarni, Kanwaljit Chopra
    Abstract:

    Diabetic neuropathic pain, an important Microvascular Complication in diabetes mellitus, has been recognized as one of the most difficult types of pain to treat. The underlying mechanisms of painful symptoms may be closely associated with hyperglycaemia but a lack of the understanding of its proper aetiology, inadequate relief, development of tolerance and potential toxicity of classical antinociceptives warrant the investigation of the newer agents to relieve this pain. The aim of the present study was to explore the antinociceptive effect of resveratrol on diabetic neuropathic pain and to examine its effect on serum tumour necrosis factor-alpha (TNF-alpha) and whole brain nitric oxide (NO) release. Four weeks after a single intraperitoneal injection of streptozotocin (STZ, 200 mg/kg), mice were tested in the tail immersion and hot-plate assays. Diabetic mice exhibited significant hyperalgesia along with increased plasma glucose and decreased body weights when compared with control mice. Daily treatment with resveratrol (5, 10 and 20 mg/kg body weight; p.o.) for 4 weeks starting from the 4th week of STZ injection significantly attenuated thermal hyperalgesia. Resveratrol also decreased the serum TNF-alpha levels and whole brain NO release in a dose-dependent manner. These results point towards the potential of resveratrol in attenuating diabetic neuropathic pain.

  • curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain
    European Journal of Pharmacology, 2006
    Co-Authors: Sameer Sharma, Srinivas K Kulkarni, Javed N Agrewala, Kanwaljit Chopra
    Abstract:

    Diabetic neuropathic pain, an important Microvascular Complication in diabetes mellitus is recognised as one of the most difficult types of pain to treat. A lack of the understanding of its aetiology, inadequate relief, development of tolerance and potential toxicity of classical antinociceptives warrant the investigation of the newer agents to relieve this pain. The aim of the present study was to explore the antinociceptive effect of curcumin and its effect on tumour necrosis factor-alpha (TNF-alpha) and nitric oxide (NO) release in streptozotocin induced diabetic mice. Four weeks after a single intraperitoneal injection of streptozotocin (200 mg/kg), mice were tested in the tail immersion and hot-plate assays. Diabetic mice exhibited significant hyperalgesia along with increased plasma glucose and decreased body weights as compared with control mice. Chronic treatment with curcumin (15, 30 and 60 mg/kg body weight; p.o.) for 4 weeks starting from the 4th week of streptozotocin injection significantly attenuated thermal hyperalgesia and the hot-plate latencies. Curcumin also inhibited the TNF-alpha and NO release in a dose dependent manner. These results indicate an antinociceptive activity of curcumin possibly through its inhibitory action on NO and TNF-alpha release and point towards its potential to attenuate diabetic neuropathic pain.

  • quercetin a bioflavonoid attenuates thermal hyperalgesia in a mouse model of diabetic neuropathic pain
    Progress in Neuro-psychopharmacology & Biological Psychiatry, 2003
    Co-Authors: Muragundla Anjaneyulu, Kanwaljit Chopra
    Abstract:

    Diabetic neuropathic pain, an important Microvascular Complication in diabetes mellitus, has been recognised as one of the most difficult types of pain to treat. Lack of understanding of etiology involved, inadequate relief, development of tolerance and potential toxicity of classical antinociceptives warrant the investigation of newer agents to relieve pain. The aim of the present study was to explore the antinociceptive effect of a bioflavonoid, quercetin, both in control and streptozotocin (STZ)-induced diabetic mice. After 4 weeks of a single intraperitoneal injection of STZ (200 mg/kg), both control and diabetic mice were subjected to test thermal hyperalgesia by tail-immersion assay (warm water). Diabetic mice exhibited a significant hyperalgesia as compared with control mice. Quercetin (100 but not 50 mg/kg po) produced a marked increase in tail-flick latencies in both diabetic and nondiabetic mice. Quercetin-induced increase in nociceptive threshold was reversed by naloxone (2 mg/kg ip), an opioid receptor antagonist. These preliminary results indicate an antinociceptive activity of quercetin, probably through modulation of opioidergic mechanism and point towards its potential to attenuate diabetic neuropathic pain.

S. A. R. B. Rombouts - One of the best experts on this subject based on the ideXlab platform.

  • Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy
    Diabetologia, 2006
    Co-Authors: A. M. Wessels, S. Simsek, P. L. Remijnse, D. J. Veltman, G. J. Biessels, F. Barkhof, P. Scheltens, F. J. Snoek, R. J. Heine, S. A. R. B. Rombouts
    Abstract:

    Aims/hypothesis In addition to nephropathy, retinopathy and peripheral neuropathy, a Microvascular Complication of type 1 diabetes that may be tentatively referred to as ‘diabetic encephalopathy’ has gained increasing attention. There is growing evidence that lowered cognitive performance in patients with type 1 diabetes is related to chronic hyperglycaemia rather than recurrent episodes of severe hypoglycaemia, as previously speculated. The aim of our study was to use magnetic resonance imaging (MRI) to establish whether long-term hyperglycaemia, resulting in advanced retinopathy, contributes to structural changes in the brain (reduced grey matter). Subjects, materials and methods We applied voxel-based morphometry on magnetic resonance images to compare grey matter density (GMD) between three groups of participants. GMD is used as a marker of cortical atrophy. We compared 13 type 1 diabetic patients with a Microvascular Complication (i.e. proliferative retinopathy) with 18 type 1 diabetic patients who did not have retinopathy in order to assess the effects of Microvascular changes on GMD. Both patient groups were compared with 21 healthy control subjects to assess the effect of diabetes in itself. Results Patients with diabetic retinopathy showed reduced GMD in the right inferior frontal gyrus and right occipital lobe compared both with patients without retinopathy and with healthy controls ( p

  • voxel based morphometry demonstrates reduced grey matter density on brain mri in patients with diabetic retinopathy
    Diabetologia, 2006
    Co-Authors: A. M. Wessels, S. Simsek, P. L. Remijnse, D. J. Veltman, G. J. Biessels, F. Barkhof, P. Scheltens, F. J. Snoek, R. J. Heine, S. A. R. B. Rombouts
    Abstract:

    Aims/hypothesis: In addition to nephropathy, retinopathy and peripheral neuropathy, a Microvascular Complication of type 1 diabetes that may be tentatively referred to as 'diabetic encephalopathy' has gained increasing attention. There is growing evidence that lowered cognitive performance in patients with type 1 diabetes is related to chronic hyperglycaemia rather than recurrent episodes of severe hypoglycaemia, as previously speculated. The aim of our study was to use magnetic resonance imaging (MRI) to establish whether long-term hyperglycaemia, resulting in advanced retinopathy, contributes to structural changes in the brain (reduced grey matter). Subjects, materials and methods: We applied voxel-based morphometry on magnetic resonance images to compare grey matter density (GMD) between three groups of participants. GMD is used as a marker of cortical atrophy. We compared 13 type 1 diabetic patients with a Microvascular Complication (i.e. proliferative retinopathy) with 18 type 1 diabetic patients who did not have retinopathy in order to assess the effects of Microvascular changes on GMD. Both patient groups were compared with 21 healthy control subjects to assess the effect of diabetes in itself. Results: Patients with diabetic retinopathy showed reduced GMD in the right inferior frontal gyrus and right occipital lobe compared both with patients without retinopathy and with healthy controls (p<0.05). Conclusions/interpretation: Our data show that patients with type 1 diabetes, who, as a consequence of chronic hyperglycaemia, had developed advanced retinopathy, also showed increased focal cortical atrophy on brain MRI.

A. M. Wessels - One of the best experts on this subject based on the ideXlab platform.

  • Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy
    Diabetologia, 2006
    Co-Authors: A. M. Wessels, S. Simsek, P. L. Remijnse, D. J. Veltman, G. J. Biessels, F. Barkhof, P. Scheltens, F. J. Snoek, R. J. Heine, S. A. R. B. Rombouts
    Abstract:

    Aims/hypothesis In addition to nephropathy, retinopathy and peripheral neuropathy, a Microvascular Complication of type 1 diabetes that may be tentatively referred to as ‘diabetic encephalopathy’ has gained increasing attention. There is growing evidence that lowered cognitive performance in patients with type 1 diabetes is related to chronic hyperglycaemia rather than recurrent episodes of severe hypoglycaemia, as previously speculated. The aim of our study was to use magnetic resonance imaging (MRI) to establish whether long-term hyperglycaemia, resulting in advanced retinopathy, contributes to structural changes in the brain (reduced grey matter). Subjects, materials and methods We applied voxel-based morphometry on magnetic resonance images to compare grey matter density (GMD) between three groups of participants. GMD is used as a marker of cortical atrophy. We compared 13 type 1 diabetic patients with a Microvascular Complication (i.e. proliferative retinopathy) with 18 type 1 diabetic patients who did not have retinopathy in order to assess the effects of Microvascular changes on GMD. Both patient groups were compared with 21 healthy control subjects to assess the effect of diabetes in itself. Results Patients with diabetic retinopathy showed reduced GMD in the right inferior frontal gyrus and right occipital lobe compared both with patients without retinopathy and with healthy controls ( p

  • voxel based morphometry demonstrates reduced grey matter density on brain mri in patients with diabetic retinopathy
    Diabetologia, 2006
    Co-Authors: A. M. Wessels, S. Simsek, P. L. Remijnse, D. J. Veltman, G. J. Biessels, F. Barkhof, P. Scheltens, F. J. Snoek, R. J. Heine, S. A. R. B. Rombouts
    Abstract:

    Aims/hypothesis: In addition to nephropathy, retinopathy and peripheral neuropathy, a Microvascular Complication of type 1 diabetes that may be tentatively referred to as 'diabetic encephalopathy' has gained increasing attention. There is growing evidence that lowered cognitive performance in patients with type 1 diabetes is related to chronic hyperglycaemia rather than recurrent episodes of severe hypoglycaemia, as previously speculated. The aim of our study was to use magnetic resonance imaging (MRI) to establish whether long-term hyperglycaemia, resulting in advanced retinopathy, contributes to structural changes in the brain (reduced grey matter). Subjects, materials and methods: We applied voxel-based morphometry on magnetic resonance images to compare grey matter density (GMD) between three groups of participants. GMD is used as a marker of cortical atrophy. We compared 13 type 1 diabetic patients with a Microvascular Complication (i.e. proliferative retinopathy) with 18 type 1 diabetic patients who did not have retinopathy in order to assess the effects of Microvascular changes on GMD. Both patient groups were compared with 21 healthy control subjects to assess the effect of diabetes in itself. Results: Patients with diabetic retinopathy showed reduced GMD in the right inferior frontal gyrus and right occipital lobe compared both with patients without retinopathy and with healthy controls (p<0.05). Conclusions/interpretation: Our data show that patients with type 1 diabetes, who, as a consequence of chronic hyperglycaemia, had developed advanced retinopathy, also showed increased focal cortical atrophy on brain MRI.

Lea Duvnjak - One of the best experts on this subject based on the ideXlab platform.

  • Preserved C-peptide secretion in patients with type 1 diabetes and incipient chronic Complications is associated with lower serum resistin and higher uric acid levels
    Journal of Diabetes & Metabolic Disorders, 2020
    Co-Authors: Tomislav Bulum, Martina Tomić, Sandra Vučković-rebrina, Vinko Roso, Marijana Vučić Lovrenčić, Lea Duvnjak
    Abstract:

    Background and aims Previous studies suggested that long-term perseverance of beta-cell function in patients with type 1 diabetes (T1DM) is associated with lower incidence of Microvascular Complications. The objective of this study was to evaluate preserved C-peptide secretion in patients with T1DM without overt chronic Complications and to explore associations with resistin and uric acid as biomarkers of Microvascular Complication pathogenesis. Materials and methods We assessed residual beta-cell function in 164 T1DM patients (male/female = 91/73; age/diabetes duration range = 18–70/1–30 years) using an ultrasensitive C-peptide ELISA assay with detection limit of 2.5 pmol/L and total coefficient of variation (CV) 5,8% (Mercodia, Sweden). Serum level of uric acid was measured by enzymatic method (AU680, Beckman Coulter, USA) while resistin concentration was determined by the ELISA assay (Biovendor, Czech Republic). Results C-peptide secretors had shorter diabetes duration (5.1 vs. 16 years; p  

P. Scheltens - One of the best experts on this subject based on the ideXlab platform.

  • Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy
    Diabetologia, 2006
    Co-Authors: A. M. Wessels, S. Simsek, P. L. Remijnse, D. J. Veltman, G. J. Biessels, F. Barkhof, P. Scheltens, F. J. Snoek, R. J. Heine, S. A. R. B. Rombouts
    Abstract:

    Aims/hypothesis In addition to nephropathy, retinopathy and peripheral neuropathy, a Microvascular Complication of type 1 diabetes that may be tentatively referred to as ‘diabetic encephalopathy’ has gained increasing attention. There is growing evidence that lowered cognitive performance in patients with type 1 diabetes is related to chronic hyperglycaemia rather than recurrent episodes of severe hypoglycaemia, as previously speculated. The aim of our study was to use magnetic resonance imaging (MRI) to establish whether long-term hyperglycaemia, resulting in advanced retinopathy, contributes to structural changes in the brain (reduced grey matter). Subjects, materials and methods We applied voxel-based morphometry on magnetic resonance images to compare grey matter density (GMD) between three groups of participants. GMD is used as a marker of cortical atrophy. We compared 13 type 1 diabetic patients with a Microvascular Complication (i.e. proliferative retinopathy) with 18 type 1 diabetic patients who did not have retinopathy in order to assess the effects of Microvascular changes on GMD. Both patient groups were compared with 21 healthy control subjects to assess the effect of diabetes in itself. Results Patients with diabetic retinopathy showed reduced GMD in the right inferior frontal gyrus and right occipital lobe compared both with patients without retinopathy and with healthy controls ( p

  • voxel based morphometry demonstrates reduced grey matter density on brain mri in patients with diabetic retinopathy
    Diabetologia, 2006
    Co-Authors: A. M. Wessels, S. Simsek, P. L. Remijnse, D. J. Veltman, G. J. Biessels, F. Barkhof, P. Scheltens, F. J. Snoek, R. J. Heine, S. A. R. B. Rombouts
    Abstract:

    Aims/hypothesis: In addition to nephropathy, retinopathy and peripheral neuropathy, a Microvascular Complication of type 1 diabetes that may be tentatively referred to as 'diabetic encephalopathy' has gained increasing attention. There is growing evidence that lowered cognitive performance in patients with type 1 diabetes is related to chronic hyperglycaemia rather than recurrent episodes of severe hypoglycaemia, as previously speculated. The aim of our study was to use magnetic resonance imaging (MRI) to establish whether long-term hyperglycaemia, resulting in advanced retinopathy, contributes to structural changes in the brain (reduced grey matter). Subjects, materials and methods: We applied voxel-based morphometry on magnetic resonance images to compare grey matter density (GMD) between three groups of participants. GMD is used as a marker of cortical atrophy. We compared 13 type 1 diabetic patients with a Microvascular Complication (i.e. proliferative retinopathy) with 18 type 1 diabetic patients who did not have retinopathy in order to assess the effects of Microvascular changes on GMD. Both patient groups were compared with 21 healthy control subjects to assess the effect of diabetes in itself. Results: Patients with diabetic retinopathy showed reduced GMD in the right inferior frontal gyrus and right occipital lobe compared both with patients without retinopathy and with healthy controls (p<0.05). Conclusions/interpretation: Our data show that patients with type 1 diabetes, who, as a consequence of chronic hyperglycaemia, had developed advanced retinopathy, also showed increased focal cortical atrophy on brain MRI.